43200-88-0

Basic information

• Product Name: 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE
• Synonyms: 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE;6-(5-CHLORO PYRID-2-YL)-7-OXO-5-PHENOXY CARBONYLOX
• CAS NO: 43200-88-0
• Molecular Formula: C₁₈H₁₁ClN₄O₄
• Molecular Weight: 382.76
• Mol File: 43200-88-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 599.5°C at 760 mmHg
• Flash Point: 316.3°C
• Appearance: /
• Density: 1.57g/cm³
• Vapor Pressure: 2.49E-14mmHg at 25°C
• Refractive Index: 1.7
• PKA: -0.63±0.29(Predicted)
• CAS DataBase Reference: 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE(43200-88-0)
• EPA Substance Registry System: 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE(43200-88-0)

Safety Data

• Hazardous Substances Data: 43200-88-0(Hazardous Substances Data)

Usage

Uses

6-(5-Chloropyrid-2-yl)-7-phenoxycarbonyloxy-6,7-dihydropyrrolo[3,4-b]pyrazin-5-one could be a useful tranquilizer and anticonvulsant.

InChI:InChI=1/C18H11ClN4O4/c19-11-6-7-13(22-10-11)23-16(24)14-15(21-9-8-20-14)17(23)27-18(25)26-12-4-2-1-3-5-12/h1-10,17H

Upstream product

• 1885-14-9 phenyl chloroformate 
• 43200-81-3 6-(5-chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one 

Downstream Products

• 43200-80-2 zopiclon 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT

The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with A

A NEW METHOD FOR PREPARATION OF ZOPICLONE AND ITS POLYMORPHS

A process for the preparation of crystalline Zopiclone comprising i) suspending zopiclone in a mixture of acetonitrile and diisopropyl ether, filtering and drying the resulting solid; ii) dissolving the solid in step i) in N,N-dimethylformamide to get a clear solution; iii) heating and then precipitating solid; iv) filtering and drying the solid to get crystalline zopiclone. Crystalline zopiclone Form C. Crystalline Zopiclone Form D characterized by an X-ray powder diffraction pattern that comprises peaks with 2theta values of at least 14.8, 19.8, 21.3, 27.3 °2θ ± 0.2 °2θ. A process for preparation of crystalline Zopiclone Form D comprising dissolving Zopiclone in N,N-dimethylformamide and filtering; washing clear filtrate with an alkali solution; separating and concentrating the organic layer, adding isopropyl alcohol thereto and concentrating further to get a slurry; filtering the slurry and drying the resultant solid to get crystalline Zopiclone form D. Pharmaceutical composition comprising crystalline forms of Zopiclone.